Exton, PA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm serving the global life sciences industry, today announced the establishment of its Respiratory Franchise, building on two years of research in the therapeutic area. The franchise brings together Spherix’s established work across asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD), supported by experienced researchers and a growing publication portfolio, with opportunities to expand into additional respiratory indications.
Spherix’s respiratory research includes more than 15 consecutive months of monthly research supported by access to qualified allergists, immunologists, and pulmonologists across the U.S. and Europe. This growing body of work provides a foundation for connecting insights across indications, specialties, and geographies as Spherix continues to broaden its respiratory coverage.
Respiratory is becoming an increasingly important area of biopharmaceutical innovation, with advances in inhaled therapies, biologics, and emerging mechanisms creating new possibilities for patients across asthma, COPD, ILD, and more. As treatment options expand, companies need a clear view of how physicians, payers, and patients are evaluating and using new therapies, how care differs by specialty and geography, and which clinical and commercial factors will shape adoption.
Through the new franchise, Spherix will connect physician, patient, and payer perspectives with the therapeutic expertise needed to interpret what those findings mean for development, launch, market access, and brand strategy. Clients will also have access to Spherix’s respiratory specialists for strategic working sessions, tailored research, prescriber analyses, and advisory support.
“Spherix has already developed a strong foundation of research across asthma, COPD, and ILD, making this the right time to establish Respiratory as its own franchise,” said Dan Barton, CEO. “This added focus will allow us to follow these markets more closely, connect insights across stakeholder groups, and provide the context clients need as treatment approaches continue to advance. These indications are our starting point, with significant opportunity to broaden our respiratory coverage over time.”
The 2026 Respiratory publication portfolio includes Market Dynamix™: Asthma, US and Market Dynamix™: Asthma, EU, providing insight into how treatment approaches, physician perceptions, unmet needs, and expectations for emerging therapies differ across the two regions. Spherix is also now providing the same deep insights and geographic perspective through Market Dynamix™: Chronic Obstructive Pulmonary Disease, US and Market Dynamix™: Chronic Obstructive Pulmonary Disease, EU.
The portfolio also includes Special Topix™: ILD in Rheumatology, US, which examines an important area of intersection between respiratory and rheumatologic care. Its inclusion reflects Spherix’s ability to maintain cross-franchise expertise while giving respiratory-focused research a distinct and clearly defined home.
The initial portfolio will expand as innovation advances and new client needs emerge, with opportunities to add respiratory indications, research formats, and stakeholder perspectives over time.
The focused Respiratory Franchise reinforces Spherix’s commitment to investing in therapeutic areas where sustained research, specialist expertise, and historical context can provide clients with a more meaningful view of the market. By formalizing an established body of respiratory research within a dedicated franchise, Spherix is positioned to deepen its coverage as the treatment landscape evolves. For more information about Spherix Global Insights and its Respiratory Franchise, visit www.spherixglobalinsights.com/respiratory.
About Spherix Global Insights
Spherix Global Insights is a leading independent provider of market intelligence and advisory services for specialty pharmaceutical and biotech markets. By combining physician, patient, and payer perspectives into an integrated view, Spherix helps brand teams, market access stakeholders, and investors understand how a specialty market actually behaves, not how any one stakeholder describes it. The firm operates ten dedicated therapeutic franchises – Dermatology, Gastroenterology, Hematology, Nephrology, Neuroscience, Obesity, Oncology, Ophthalmology, Respiratory and Rheumatology – plus a Market Access team. Each franchise is staffed by hyper-focused experts who track these markets full-time, drawing on independently curated communities of vetted specialists, patients, and payers to deliver quarterly trending, launch tracking, chart audits, and KOL synthesis. Trusted by 19 of the top 20 pharmaceutical and biotech organizations, Spherix has been a go-to resource for more than a decade for leading brands, industry media, financial analysts, and patient advocacy groups.
To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com
NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insights’ analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.
Andy Stankus, Franchise Head, Dermatology and Respiratory Spherix Global Insights 484-879-4284 andy.stankus@spherixglobalinsights.com